Biotech Values

[oc631]

Why need to measure for efficacy for 16 and 24-weeks if 8 and 12 was sufficient from other trial with GT1 patients?

You are right Sofo/Riba will never be used in GT1 outside of this study. So why run the study? GILD is insecure about achieving GT3 labeling for Sofo/Riba so running this study looks good on the resume. Even though SVR data won't read-out until after a decision has been made by the FDA. I would love to hear other theories. When you are one of the dumb members on this board, speculation is O.K., because your reputation is intact.


I would like to hear other theories.